Influenza-M1-58_66
Influenza A matrix protein 1 peptide epitope GILGFVFTL (aa 58-66)
GILGFVFTL Amino Acids · MW: 939.1
Amino Acids
GILGFVFTL
Molecular Weight
939.1
Half-life
minutes-hours
Research Score
4.5
Studies
95
Storage
Store lyophilized at -20°C, reconstituted at 2-8°C
What is Influenza-M1-58_66?
A classic HLA-A*0201 influenza epitope used in peptide vaccine and T-cell epitope studies. It is a benchmark viral antigen for eliciting strong CD8+ T-cell responses.
Key Benefits & Mechanisms
benchmark viral epitope
CD8+ T-cell priming
useful for assay validation
Research Summary
GILGFVFTL is one of the best-characterized human influenza epitopes and is frequently included in peptide vaccine research. Its reliability makes it useful for both therapeutic vaccination and immunomonitoring.
Related Peptides
PADRE
Pan HLA-DR-binding helper T-cell epitope
PADRE is a synthetic promiscuous CD4+ helper T-cell epitope designed to bind many HLA-DR alleles. It is widely used in peptide vaccine research to improve helper T-cell priming and strengthen responses to linked antigens.
Vaccine PeptidesSIINFEKL
Ovalbumin 257-264 epitope (SIINFEKL)
SIINFEKL is a classic MHC class I epitope derived from chicken ovalbumin. It is one of the most widely used model peptides for studying antigen presentation, cytotoxic T-cell priming, and peptide vaccine platforms.
Vaccine PeptidesAAGIGILTV
MART-1/Melan-A 26-35 epitope
AAGIGILTV is a well-known HLA-A2-restricted epitope from the melanocyte differentiation antigen MART-1/Melan-A. It has been studied in melanoma vaccine research to generate antigen-specific T-cell responses against tumor cells.
Vaccine PeptidesHPV16 E7(11-20)
Human papillomavirus type 16 E7 11-20 epitope
HPV16 E7(11-20) is a documented cytotoxic T-cell epitope derived from the HPV16 E7 oncoprotein. It has been used in therapeutic HPV vaccine research to stimulate epitope-specific cellular immunity.
Vaccine Peptides